CALZF (Polynovo) Total Current Liabilities: $15.16 Mil (As of Dec. 2025)


CALZF Polynovo Ltd CALZF
75 GF Score
Price $0.62
GF Value $2.26
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Polynovo Total Current Liabilities?

Polynovo CALZF 75 Total Current Liabilities is $15.16 Mil as of Dec. 2025. GuruFocus rates CALZF with a GF Score™ of 75/100 and a GF Value™ of $2.26 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Polynovo's total current liabilities for the quarter that ended in Dec. 2025 was $15.16

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Polynovo Total Current Liabilities Related Terms

Polynovo Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Polynovo's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polynovo Total Current Liabilities Chart

Polynovo Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.61 5.45 8.50 15.44 18.15

Polynovo Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.39 15.44 14.46 18.15 15.16
CALZF
75GF Score
Polynovo Ltd CALZF
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polynovo Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Polynovo's Total Current Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=14.674+1.567
+Other Current Liabilities+Current Deferred Liabilities
=1.718+0.193
=18.15

Polynovo's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=10.735+1.858
+Other Current Liabilities+Current Deferred Liabilities
=2.191+0.374
=15.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $15.16 Mil mean?
Polynovo (CALZF) has a Total Current Liabilities of $15.16 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Polynovo and its competitors.
Is Polynovo's Total Current Liabilities too high?
Polynovo's current Total Current Liabilities is $15.16 Mil. Overall, Polynovo has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Total Current Liabilities compare to ABT and SYK?
Polynovo's Total Current Liabilities of $15.16 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Polynovo and its competitors. Polynovo's current Total Current Liabilities is $15.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.26, compared to a current price of $0.62 — trading 72.6% below its estimated fair value. The current Total Current Liabilities is $15.16 Mil. Polynovo's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Polynovo (CALZF), the current Total Current Liabilities is $15.16 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Polynovo (CALZF) Overvalued in 2026?

Based on GuruFocus' analysis, Polynovo stock appears to be undervalued. The current stock price of $0.62 is trading 72.6% below its estimated GF Value™ of $2.26. GuruFocus considers Polynovo to be Significantly Undervalued.

Key valuation signals for CALZF:

  • Total Current Liabilities: $15.16 Mil
  • GF Value™: $2.26 vs. price of $0.62 (72.6% below fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Polynovo Business Description

Other Exchanges MFJ:GermanyPNV:Australia
Address 320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
75GF Score

Get the complete analysis for CALZF

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.62
Price
$2.26
GF Value